Manufacturing briefing: After J&J-Emergent mixup, fewer doses expected in US next week; Boehringer taps Oxford for viral vectors
Americans will see a significant drop in J&J Covid-19 vaccines allocated next week, according to data from the CDC.
A report from Reuters noted that just 785,500 doses will be doled out, compared to 4.95 million this week.
The New York Times previously reported that a mixup at a Baltimore Emergent facility resulted in 15 million future doses being ruined. California is the main recipient of the J&J vaccine, followed by Texas and Florida, Reuters said.
Weeks after Sanofi backed out of viral vectors deal, Oxford inks agreement with Boehringer Ingelheim
Oxford Biomedica announced Tuesday that it signed a new three-year deal with Boehringer Ingelheim for the manufacturing and supply of viral vectors.
Oxford will manufacture batches for Boehringer Ingelheim for a supply of various types of viral vectors, a release said.
The deal is the latest in a partnership between the two companies started in 2018.
“We now have a portfolio of partnerships spread across development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, utilising lentiviral vectors,” Oxford CEO John Dawson said in a statement. “We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs.”
The UK tries to spur manufacturing investment at home with new grant fund
In a move to encourage manufacturing at home, the UK government announced a fund through which manufacturers can now apply for a share of up to $27.5 million.
The money is open to private manufacturers in human medicine, medical diagnostics and medtech. The program is geared at creating jobs and economic growth, as well as create products that will “contribute to the building of the UK’s health resilience.”
Those who receive funding will have so for one year. To be eligible, applicants must be able to spend the money before next March. Businesses will have to confirm that their eligible costs are greater than $10.99 million. Companies must also be able to proceed with the project, without delay, within four weeks.
Supply chain companies are not eligible for the funding, and the money cannot be used for salaries, R&D or training.
“During the application process, you will also be asked to confirm that the project cannot viably proceed without public sector support,” the scheme guidance states.
The application deadline is June 30 at 11:59 p.m.